NCT05806814
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentUniversity of OklahomaInvestigator-initiated
~15 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:Sipuleucel-T
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of patients completing 3 doses of Sipuleucel-T immunotherapy.
Measured over up to 5 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesOklahoma1
Study leadership
- Kelly Stratton, MD · PRINCIPAL_INVESTIGATOR · Investigator
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Proportion of patients completing 3 doses of Sipuleucel-T immunotherapy.up to 5 months
Patients will be treated with Sipuleucel-T immunotherapy and the treatment regimen will be considered feasible if 85% of enrolled patients complete all three infusions of Sipuleucel-T treatment given at week 0, 2 and 12-14.
- Proportion of subjects who have detectable elevated IgG level and/or T-cell proliferation from baseline to the follow-up of extended course of Sipuleucel-T immunotherapy.up to 12 Months
For patients undergoing Sipuleucel-T treatment on weeks 0, 2 and 12-14, the changes in immune response will be measured based on the detectable elevated levels of IgG and/or T-cell proliferation against various types of prostate cancer associated antigens at baseline, and at Sipuleucel-T infusion doses given at week 0, 2 and 12-14 weeks.